• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HER2阳性和三阴性类正常型猫乳腺肿瘤亚型中的血清PD-1/PD-L1水平、肿瘤表达及PD-L1体细胞突变

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.

作者信息

Nascimento Catarina, Urbano Ana Catarina, Gameiro Andreia, Ferreira João, Correia Jorge, Ferreira Fernando

机构信息

CIISA-Centro de Investigação Interdisciplinar em Sanidade Animal, Faculdade de Medicina Veterinária, Universidade de Lisboa, Avenida da Universidade Técnica, 1300-477 Lisboa, Portugal.

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal.

出版信息

Cancers (Basel). 2020 May 28;12(6):1386. doi: 10.3390/cancers12061386.

DOI:10.3390/cancers12061386
PMID:32481540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7352561/
Abstract

Tumor microenvironment has gained great relevance due to its ability to regulate distinct checkpoints mediators, orchestrating tumor progression. Serum programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) levels were compared with healthy controls and with serum cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and tumor necrosis factor-alpha (TNF-α) levels in order to understand the role of PD-1/PD-L1 axis in cats with mammary carcinoma. PD-1 and PD-L1 expression was evaluated in tumor-infiltrating lymphocytes (TILs) and cancer cells, as the presence of somatic mutations. Results showed that serum PD-1 and PD-L1 levels were significantly higher in cats with HER2-positive ( = 0.017; = 0.032) and triple negative (TN) normal-like mammary carcinomas ( = 0.004; = 0.015), showing a strong positive correlation between serum CTLA-4 and TNF-α levels. In tumors, PD-L1 expression in cancer cells was significantly higher in HER2-positive samples than in TN normal-like tumors ( = 0.010), as the percentage of PD-L1-positive TILs ( = 0.037). gene sequencing identified two heterozygous mutations in exon 4 (A245T; V252M) and one in exon 5 (T267S). In summary, results support the use of spontaneous feline mammary carcinoma as a model for human breast cancer and suggest that the development of monoclonal antibodies may be a therapeutic strategy.

摘要

肿瘤微环境因其调节不同检查点介质、协调肿瘤进展的能力而变得至关重要。将血清程序性细胞死亡蛋白1(PD-1)和程序性死亡配体1(PD-L1)水平与健康对照进行比较,并与血清细胞毒性T淋巴细胞相关抗原4(CTLA-4)和肿瘤坏死因子-α(TNF-α)水平进行比较,以了解PD-1/PD-L1轴在猫乳腺癌中的作用。评估肿瘤浸润淋巴细胞(TILs)和癌细胞中PD-1和PD-L1的表达,以及体细胞突变的存在情况。结果显示,HER2阳性(P = 0.017;P = 0.032)和三阴性(TN)正常样乳腺癌猫的血清PD-1和PD-L1水平显著更高(P = 0.004;P = 0.015),血清CTLA-4和TNF-α水平之间呈强正相关。在肿瘤中,HER2阳性样本中癌细胞的PD-L1表达显著高于TN正常样肿瘤(P = 0.010),PD-L1阳性TILs的百分比也是如此(P = 0.037)。基因测序在第4外显子中鉴定出两个杂合突变(A245T;V252M),在第5外显子中鉴定出一个突变(T267S)。总之,结果支持将自发性猫乳腺癌用作人类乳腺癌的模型,并表明单克隆抗体的开发可能是一种治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/4ee4be50e841/cancers-12-01386-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/216c820fdbe3/cancers-12-01386-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/6391d866fde8/cancers-12-01386-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/3240c30b118b/cancers-12-01386-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/4e2ea473e45d/cancers-12-01386-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/4ee4be50e841/cancers-12-01386-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/216c820fdbe3/cancers-12-01386-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/6391d866fde8/cancers-12-01386-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/3240c30b118b/cancers-12-01386-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/4e2ea473e45d/cancers-12-01386-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ff/7352561/4ee4be50e841/cancers-12-01386-g005.jpg

相似文献

1
Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.HER2阳性和三阴性类正常型猫乳腺肿瘤亚型中的血清PD-1/PD-L1水平、肿瘤表达及PD-L1体细胞突变
Cancers (Basel). 2020 May 28;12(6):1386. doi: 10.3390/cancers12061386.
2
VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.VISTA是侵袭性猫乳腺癌亚型的诊断生物标志物和免疫治疗靶点。
Cancers (Basel). 2021 Nov 5;13(21):5559. doi: 10.3390/cancers13215559.
3
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, -like status, tumor-infiltrating immune cells and survival.评估乳腺癌分子亚型中PD-L1的表达情况,及其与突变率、-样状态、肿瘤浸润免疫细胞和生存率的关系。
Oncoimmunology. 2018 Sep 11;7(12):e1509820. doi: 10.1080/2162402X.2018.1509820. eCollection 2018.
4
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.免疫检查点调节剂、细胞毒性 T 淋巴细胞抗原 4(CTLA-4)和程序性死亡配体 1(PD-L1)在女性乳腺癌中的表达。
PLoS One. 2018 Apr 19;13(4):e0195958. doi: 10.1371/journal.pone.0195958. eCollection 2018.
5
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.德国辅助性肿瘤组淋巴结阳性研究中高危、淋巴结转移的乳腺癌患者肿瘤浸润淋巴细胞、PD-1 和 PD-L1 的相关性。
Eur J Cancer. 2019 Jun;114:76-88. doi: 10.1016/j.ejca.2019.04.010. Epub 2019 May 7.
6
Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.瘦素和瘦素受体的血清及组织表达水平是特定猫乳腺肿瘤亚型的潜在标志物。
Front Vet Sci. 2021 Feb 10;8:625147. doi: 10.3389/fvets.2021.625147. eCollection 2021.
7
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.Foxp3+/CD25+ 调节性 T 细胞和 PD-L1 表达在三阴性乳腺癌中的预测和预后价值。
Ann Diagn Pathol. 2019 Jun;40:143-151. doi: 10.1016/j.anndiagpath.2019.04.004. Epub 2019 Apr 10.
8
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌(TNBC)中肿瘤浸润淋巴细胞(TILs)和程序性死亡配体 1(PD-L1)表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
9
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
10
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.胃腺癌中免疫检查点程序性死亡1配体1和细胞毒性T淋巴细胞相关分子4
Oncoimmunology. 2015 Nov 9;5(5):e1100789. doi: 10.1080/2162402X.2015.1100789. eCollection 2016 May.

引用本文的文献

1
PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors.PD-1、PD-L1和PD-L2表达作为罕见猫乳腺肿瘤的预测标志物
Vet Sci. 2025 Aug 3;12(8):731. doi: 10.3390/vetsci12080731.
2
Phosphoproteomic profiling of feline mammary carcinoma: Insights into tumor grading and potential therapeutic targets.猫乳腺癌的磷酸化蛋白质组学分析:对肿瘤分级及潜在治疗靶点的见解
PLoS One. 2025 Aug 21;20(8):e0330520. doi: 10.1371/journal.pone.0330520. eCollection 2025.
3
Comparison of the Efficacy and Safety of PD-1/PD-L1 Inhibitors in the Treatment of Small Cell Lung Cancer.

本文引用的文献

1
Immunotherapy for Breast Cancer: First FDA Approved Regimen.乳腺癌免疫疗法:首个获美国食品药品监督管理局批准的方案。
Discoveries (Craiova). 2019 Mar 31;7(1):e91. doi: 10.15190/d.2019.4.
2
Mouse models of colorectal cancer: Past, present and future perspectives.结直肠癌的小鼠模型:过去、现在和未来的展望。
World J Gastroenterol. 2020 Apr 7;26(13):1394-1426. doi: 10.3748/wjg.v26.i13.1394.
3
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.乳腺癌中HER2与PD-1/PD-L1的相互作用:从临床应用到数学模型
PD-1/PD-L1抑制剂治疗小细胞肺癌的疗效与安全性比较
Cancer Rep (Hoboken). 2025 Jan;8(1):e70081. doi: 10.1002/cnr2.70081.
4
Analysis of serum peptidome profiles of non-metastatic and metastatic feline mammary carcinoma using liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法分析无转移和转移的猫乳腺肿瘤的血清肽组谱。
BMC Vet Res. 2024 Jun 29;20(1):280. doi: 10.1186/s12917-024-04148-y.
5
Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.兽医肿瘤学中免疫疗法的人类生物治疗的潜在前景与风险
Vet Sci. 2023 May 9;10(5):336. doi: 10.3390/vetsci10050336.
6
Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1.抗人程序性细胞死亡配体 1(PD-L1)单克隆抗体,克隆 28-8 与猫 PD-L1 的交叉反应性。
J Vet Med Sci. 2023 Jun 1;85(6):592-600. doi: 10.1292/jvms.23-0003. Epub 2023 May 2.
7
Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.可溶性 PD-L1 和外泌体 PD-L1 在接受系统化疗的晚期胃癌患者中的预后价值。
Sci Rep. 2023 Apr 28;13(1):6952. doi: 10.1038/s41598-023-33128-9.
8
Development of anti-feline PD-1 antibody and its functional analysis.抗猫 PD-1 抗体的研制及其功能分析。
Sci Rep. 2023 Apr 24;13(1):6420. doi: 10.1038/s41598-023-31543-6.
9
Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves.通过阻断犊牛的程序性死亡配体1(PD-L1)增强疫苗诱导的T细胞反应。
Vaccines (Basel). 2023 Mar 1;11(3):559. doi: 10.3390/vaccines11030559.
10
Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway.EMT6 鼠乳腺肿瘤细胞系获得性放射抵抗是由 CTLA-4 和 PD-1 通过 JAK/STAT/PI3K 通路介导的。
Sci Rep. 2023 Feb 22;13(1):3108. doi: 10.1038/s41598-023-29925-x.
Cancers (Basel). 2020 Mar 10;12(3):636. doi: 10.3390/cancers12030636.
4
Clinical Relevance of the serum CTLA-4 in Cats with Mammary Carcinoma.猫乳腺肿瘤患者血清 CTLA-4 的临床相关性。
Sci Rep. 2020 Mar 2;10(1):3822. doi: 10.1038/s41598-020-60860-3.
5
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer.免疫检查点在乳腺癌循环肿瘤细胞中的临床相关性
Cancers (Basel). 2020 Feb 6;12(2):376. doi: 10.3390/cancers12020376.
6
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.基线血清PD-1或PD-L1水平升高预示着转移性黑色素瘤患者接受PD-1抑制治疗的预后较差。
Ann Oncol. 2020 Jan;31(1):144-152. doi: 10.1016/j.annonc.2019.09.005.
7
PD-L1 status in breast cancer: Current view and perspectives.乳腺癌中PD-L1的状态:当前观点与展望
Semin Cancer Biol. 2021 Jul;72:146-154. doi: 10.1016/j.semcancer.2019.12.003. Epub 2019 Dec 26.
8
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.血清 PD-L1 水平高是手术治疗食管癌的预后不良生物标志物。
Cancer Med. 2020 Feb;9(4):1321-1327. doi: 10.1002/cam4.2789. Epub 2019 Dec 21.
9
The clinical significance of soluble PD-1 and PD-L1 in lung cancer.可溶性 PD-1 和 PD-L1 在肺癌中的临床意义。
Crit Rev Oncol Hematol. 2019 Nov;143:148-152. doi: 10.1016/j.critrevonc.2019.08.009. Epub 2019 Sep 11.
10
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.绘制用于免疫肿瘤治疗的程序性细胞死亡配体-1 预测性免疫组织化学检测中使用的抗体结合位点图谱。
Mod Pathol. 2020 Apr;33(4):518-530. doi: 10.1038/s41379-019-0372-z. Epub 2019 Sep 26.